

Emerging applications of asymmetric dihydroxylation chemistry

Y. JAYAMMA, E. NANDANAN AND B.B. LOHRAY*

Division of Organic Chemistry (Synthesis), National Chemical Laboratory, Pune 411 008, India.

Received on February 11, 1994.

Abstract

Applications of recently discovered asymmetric dihydroxylation (ADH) of alkenes in synthetic organic chemistry have been described. ADH reaction has been successfully implemented in the synthesis of several natural products, drugs and drug intermediates. It has also been utilized in kinetic resolution and double diastereoselections in a few cases.

Key words: ADH, oxidation, unfunctionalized alkenes, diols.

1. Introduction





During 80s much attention was focussed on the asymmetric catalytic reactions¹. Stereoselective oxidation is one of the major goals in organic chemistry. Discovery of Sharpless catalytic asymmetric epoxidation is a landmark in the oxidation chemistry, which utilizes allylic alcohols as substrates². However, stereoselective oxidation of unfunctionalized olefins is a much tougher goal to achieve, especially in a catalytic fashion. In 1988, once again, a major breakthrough in the successful oxidation of unfunctionalized alkenes to diols was reported by Sharpless and co-workers³. Since the discovery of ADH reaction, a number of new chiral ligands and reaction conditions have been developed for the continuous improvement of enantioselective oxidation of alkenes (Chart 1). In 1992, we have compiled literature through 1991⁴; however, during the last two years, more emphasis has been laid on the application of this novel reaction. The present paper will cover literature up to November 1993 and this review should be treated as complementary to the previously published one⁴.

2. Applications




2.1. Stereoselective syntheses of natural products

One of the earliest applications of asymmetric dihydroxylation strategy has been reported by Tomioka *et al*⁵ for the synthesis of anthracycline antibiotics, though the reaction was carried out using stoichiometric amount of chiral auxiliary and osmium tetroxide. A very expeditious

* For correspondence.

**DHQD-CLB**Sharpless *et al**J. Am. Chem. Soc.*, 1988**DHQD-PHN**Sharpless *et al**J. Org. Chem.*, 1991**DHQD₂-PHAL**Sharpless *et al**J. Org. Chem.*, 1992**DHQD₂-TP**


Lohray and Bhushan

Tetrahedron Lett., 1992**DHQD₂-PY**Corey *et al**J. Am. Chem. Soc.*, 1993Sharpless *et al**J. Am. Chem. Soc.*, 1993Lohray *et al*

Unpublished results


Chart 1.

synthesis of anthracycline was achieved using asymmetric dihydroxylation reaction as a key step to introduce the chirality in the molecule (Scheme 1).




SCHEME 1.

Kelly and co-workers⁶ have generated the B ring diol in the planned synthesis of pradimicinone *via* ADH reaction (Scheme 2).




SCHEME 2.

Cooper and Salomon⁷ synthesized the pentacyclic intermediate from readily available ribofuranoside which is finally used in the synthesis of antitumor agent Halichondrin B (Scheme 3).




SCHEME 3.

An inverse approach to achieve diastereoselective dihydroxylation was carried out by Arjona *et al*⁸ by using chiral substrates and osmium tetroxide with NMO as co-oxidant. They have prepared *myo*-inositols from Conduritol B acetate using dihydroxylation as the key step (eqn 1).




Myo-inositol has been a useful synthetic target due to well-documented biological activities of its derivatives⁹. Similar approach has been adopted by Honda and co-workers¹⁰ to synthesize monocrotaline, a natural product, which is a 11-membered alkaloid.

The macrocyclic lactone is made up of two parts, necine base, retronecine and monocrotalic acid (Scheme 4). Monocrotalic acid was synthesized by dihydroxylation of chiral pyrones.



SCHEME 4.


Similarly, Ireland *et al*¹¹ have prepared chiral epoxide *via* diol prepared by Sharpless asymmetric dihydroxylation method. The epoxide was finally used in the synthesis of FK-506. Ikemoto and Schreiber¹² used ADH method for preparing polyols from the corresponding olefins in the synthesis of Hikizimycin, an antihelminthic agent. Kim and Sharpless¹³ prepared β -lactams from 2,3-dihydroxyesters *via* cyclic sulfites (Scheme 5).



SCHEME 5.


Zhou and co-workers¹⁴ have examined several substrates under ADH conditions for the synthesis of the plant growth regulators, brassinolide and its analogues, such as homobrassinolide,

epibrassinolide, etc. The critical step in this synthesis is the generation of the required stereochemistry at 22 and 23 position of the steroidal side chain which can be achieved by choosing the proper chiral auxiliary (*i.e.*, DHQD-CLB, dihydroquinine-*p*-chlorobenzoate). More recently, Brosa and co-workers¹⁵ obtained an improved ratio of the desired stereoisomers, 2.6:1 by using dihydroquinidine-9-*O*-(9'-phenanthryl)ether (DHQD-PHN) as a chiral ligand and *N*-methylmorpholine-*N*-oxide as co-oxidant.




Brassinolide

McMorris and Patil¹⁶ used an alternative route to synthesize 24-epibrassinolide from ergosterol using ADH reaction. The ratio of 22(*R*), 23(*R*) diol increased greatly by using DHQD-CLB in *t*-BuOH/H₂O with K₃Fe(CN)₆-K₂CO₃ as co-oxidant and even better selectivity was observed using bisdihydroquinidiny-9-*O*-phthalazine, DHQD₂-PHAL(10:1) in favour of the desired diol. Santiago and Soderquist¹⁷ and Turpin and Weigel¹⁸ almost simultaneously used asymmetric dihydroxylation as the key step in a short and elegant synthesis of (*S*)-(-)-frontalin, the aggregation pheromone of southern pine beetle, although the approaches were slightly different as shown in Schemes 6 and 7.




SCHEME 6.

A similar skeleton of 7,7-dimethyl-6,8-dioxabicyclo[3.2.1]octane which is a constituent of a volatile aroma of beer was synthesized by Sharpless *et al*^{19a} (Scheme 8a). Sharpless and



SCHEME 7.

co-workers^{19b} also used ADH reaction towards a general approach for quick entry to several γ -lactones in high enantiomeric purity and applied this for a short synthesis of (-) and (+)-muricatacin, an acetogenin derivative that shows some cytotoxicity on human tumor cells (Scheme 8b).




SCHEME 8.


Keinan *et al*²⁰ have used ADH reaction for the synthesis of all the four isomers of disparlure, a sex attractant emitted by the female Gypsy moth, *Porthetria dispar*. The active pheromone is (+)-(7*R*,8*S*)-*cis*-7,8-epoxy-2-methyloctadecane which plays a significant role in the pest control. Here they report a convergent synthesis of all the possible isomers (Scheme 9).

Bennani and Sharpless²¹ have achieved the synthesis of (+)-coriolic acid in which the resultant diol, obtained by ADH reaction of the desired β,γ -unsaturated amide, undergoes dehydration to furnish γ -hydroxy- α,β -unsaturated amide, which is finally transformed to (+)-coriolic acid (Scheme 10).

Crispino and Sharpless²² reported the synthesis of juvenile hormone (III) in three steps




SCHEME 9.



SCHEME 10.


from methyl farnesoate using selective dihydroxylation followed by conversion of diol to epoxide (Scheme 11).



SCHEME 11.

2.2. Drugs and drug intermediates


In Section 2.1, we have laid emphasis on the synthesis of several natural products and antibiotics which are biologically active and relevant molecules. In this section, we shall focus our attention on the synthesis of drug and drug intermediates. For example, Watson and co-workers²³ reported the first example of asymmetric dihydroxylation strategy towards the synthesis of a potent vasodilating agent, (+)-(2*S*,3*S*)-*cis*-diltiazem hydrochloride (Scheme 12). The diol was converted



SCHEME 12.


either into *cis*-epoxide or haloacetate which was then reacted with aminothiophenol to furnish *threo*-(2*S*,3*S*)thioether, a crucial intermediate in the synthesis of diltiazem.

Rama Rao *et al*²⁴ have prepared optically active(*S*)-propranolol using ADH reaction of α -naphthyl allyl ether, followed by conversion of diol to epoxide(Scheme 13). The epoxide was then converted into (*S*)-propranolol by a conventional method, *i.e.*, by treatment with isopropyl amine.




SCHEME 13.

Asymmetric synthesis of chloramphenicol has also been reported from the same research group²⁵ using both asymmetric epoxidation strategy as well as asymmetric dihydroxylation methodology with ethyl *p*-nitrocinnamate (Scheme 14).



SCHEME 14.


Sharpless and co-workers²⁶ have recently synthesized (*R*)-carnitine and (*R*)- γ -amino- β -hydroxybutyric acid (GABOB) which have potential usefulness as pharmaceuticals. GABOB is an antiepileptic and hypotensive drug and (*R*)-carnitine is a vitamin-like compound (Vitamin B₇), which is responsible for regulating the transport of long-chain fatty acids through mitochondrial membrane. Both these important class of compounds can be synthesized from a common intermedite (Scheme 15).



SCHEME 15.

2.3. Double diastereoselection and kinetic resolution


The concept of double diastereoselection²⁷ was introduced for ever-increasing demand of higher selectivity in stereoselective reactions. In asymmetric dihydroxylation of olefins also, the stereoselective outcome of the reactions get affected by the presence of a pre-existing chiral information in the substrate. This concept is usually exploited in kinetic resolution of a substrate using a chiral ligand. In matched cases where the chirality information of the reagent and substrate act synergistically, a higher order of stereoselectivity is usually observed. In contrast, if they exert their influence in opposite directions (mismatched cases) poor diastereoselectivity usually results. All the enzymatic or reagent-initiated kinetic resolutions are artifacts of this phenomenon and the extent of kinetic resolution depends on how best the match pair works synergistically and with what rate the reaction occurs. Annunziata *et al*²⁸ used this concept in asymmetric dihydroxylation of γ -chirality-substituted α,β -unsaturated



SCHEME 16.


esters using DHQD–CLB as a chiral ligand in ADH reaction leading to >45:1 selectivity in favour of *anti*-diastereoselection (Scheme 16).

Sharpless and co-workers^{29,30} have also reported an enhanced diastereoselectivity in the presence of an alkaloid derivative. For example, in the absence of DHQD–CLB, both substrates 1 and 2 showed poor diastereofacial bias, *i.e.*, 2.1:1 (for 1) and 1:1.1 (for 2), whereas in the presence of DHQD–CLB, they furnished 76 and 52% *de*, respectively (Scheme 17). More recently, the use of (DHQD)₂–PHAL enhanced the ratio of major isomers up to 39:1.



SCHEME 17.

Ward and Procter³¹ and Panek and Zhang³² independently carried out double asymmetric induction using chiral allylsilanes. Initially, these authors carried out asymmetric dihydroxylation of *anti*-allylsilanes using various co-oxidants (Scheme 18).



SCHEME 18.

Using double stereodifferentiation method with DHQD–CLB for a matched pair and DHQ–CLB for a mismatched pair, the selectivity observed was 91:9 and 43:57, respectively. These lactones are used as key intermediates in the synthesis of baciphelacin, an antiviral, antileukemic antibiotic.






Fig 1 Transition state for the reaction of (A) *R*-allylic acetate, and (B) *S*-allylic acetate.



SCHEME 21

auxiliary. The maximum selectivity factor (*S*) was 32.0 using (DHQD)₂-PHAL as the catalyst.

Annunziata *et al*³⁶ have carried out asymmetric dihydroxylation of racemic 4-(2-styryl)-azetidin-2-one and found that *syn* vs *anti* attack on the azetidin-2-one ranges between 50:50 and 60:40; however, % ee of *syn* and *anti* products was achieved to a respectable level of selectivity (*ca* 80–94% ee). These authors attributed the poor diastereoselection in kinetic resolution of azetidin-2-one to the equal facility of attack by osmium reagent in the transition state (Scheme 22).




SCHEME 22.

2.7. Stereoselective transformation of diols


After the pioneering discovery of the catalytic asymmetric dihydroxylation of alkenes by Sharpless and co-workers, it was mandatory to demonstrate the utilities of these diols in synthetic organic chemistry. Gao and Sharpless³⁷, during the synthetic elaboration of these optically pure diols, discovered the usefulness of cyclic sulfate esters of 1,2-diols and reported stereoselective transformation of these diols to several other functional groups by a number of nucleophiles (Scheme 23).

The emerging utilities of cyclic sulfates and sulfites have been reviewed extensively³⁸ which gives a complete account up to July 1992 and hence this topic will not be covered in this review. Apart from cyclic sulfates, we have demonstrated³⁹ the usefulness of cyclic sulfites themselves as useful synthons for converting diols into several amino alcohols, and aziridines (Scheme 24).

During the last one year, a few more applications of cyclic sulfite and cyclic sulfate




SCHEME 23.




SCHEME 24.

chemistry have been reported which only will be highlighted. For example, Kang *et al*⁴⁰ have converted unsaturated vinylic diols to allylic cyclic carbonates, sulfites or sulfates and carried out nucleophilic attack at the allylic carbon using several organocuprate or Pd(O)-catalysed nucleophilic addition reaction affording high yields of optically active allylic alcohols (Scheme 25).




SCHEME 25.

More recently, Ko and Malik⁴¹ have reported the synthesis of carbohydrates and related polyhydroxylated compounds employing asymmetric dihydroxylation followed by cyclic sulfate chemistry (Scheme 26).




SCHEME 26.

Sharpless *et al.*⁴² have converted diols into *trans*-epoxides via monotosylate/bromohydrin (Scheme 27).




SCHEME 27.

Xu and Sharpless⁴³ have prepared oxazolidine-2-one by treating vinylic diols with tosylisocyanate in the presence of a catalytic amount of Pd(O) in refluxing THF (Scheme 28).



SCHEME 28

The most interesting feature of this transformation is the retention of configuration at both the stereogenic centers and this offers a good method for the preparation of *cis* amino alcohols. Iida and Itaya⁴⁴ treated several 1,2-diols with oxalyl chloride to furnish a mixture of cyclic carbonate and 1,4-dioxan-2,3-diones. The ratio of carbonate vs dioxane derivatives depends upon the nature of the substituent on the glycol moiety (Scheme 29).



SCHEME 29.

To summarize, the applications of asymmetric dihydroxylation of alkenes in synthetic organic chemistry is gaining ground slowly, even when the process to improve the selectivity in ADH reaction and understanding the origin of selectivity is continuing to evolve. We anticipate many more applications to emerge in the near future and this review just presents the state of art how a synthetic organic chemist can exploit this novel tool.

Acknowledgement

We are thankful to DST, New Delhi, and AvH Foundation, Germany, for financial assistance. YJ and EN thank the CSIR, New Delhi, for fellowship.

References

- MORRISON, J. D. *Asymmetric synthesis*, Vol. 5, 1985, Academic Press.
- KATSUKI, T. AND SHARPLESS, K. B. *J. Am. Chem. Soc.*, 1980, **102**, 5974–5976.
- JACOBSEN, E.N., MARKO, I., MUNGALL, W.S., SCHRODER, G. AND SHARPLESS, K. B. *J. Am. Chem. Soc.*, 1988, **110**, 1968–1970.
- LOHRAY, B. B. *Tetrahedron Asymmetry*, 1992, **3**, 1317–1349.
- TOMIOKA, K., NAKAJIMA, M. AND KOGA, K. *J. Am. Chem. Soc.*, 1987, **109**, 6213–6215.

- 6 KELLY, T. R., BHUSHAN, V. AND LI, Q. *Tetrahedron Lett.*, 1990, **31**, 161-164.
- 7 COOPER, A. J. AND SALOMON R. G. *Tetrahedron Lett.*, 1990, **31**, 3813-3816.
- 8 ARJONA, O., CANDILEJO, A., DE DIOS, A., FERNANDEZ, R., PRADILLA, DE LA AND PLUMEL, J. *J. Org. Chem.*, 1992, **57**, 6097-6099.
- 9 REITZ, A. B. *ACS Symposium Series 463, American Chemical Society, Washington, DC, 1991.*
- 10 HONDA, T., TOMITSUKA, K. AND TOUBUKI, M. *J. Org. Chem.*, 1993, **58**, 4274-4279.
- 11 IRELAND, R. E., WIFE, P. AND ROPER, T. D. *J. Org. Chem.*, 1990, **55**, 2284-2285.
- 12 IKEMOTO, N. AND SCHREIBER, S. L. *J. Am. Chem. Soc.*, 1990, **112**, 9657-9659.
- 13 KIM, B. M. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1990, **31**, 4317-4320.
- 14 SUN, L.-Q., ZHOU, W.-S., PAN, X.-F. *Tetrahedron Asymmetry*, 1991, **2**, 973-976.
- 15 BROSA, C., PERACAULA, R., PUIG, R. AND VENTURA, M. *Tetrahedron Lett.*, 1992, **33**, 7057-7060.
- 16 MCMORRIS, T. C. AND PATIL, P. A. *J. Org. Chem.*, 1993, **58**, 2338-2339.
- 17 SANTIAGO, B. AND SODERQUIST, J. A. *J. Org. Chem.*, 1992, **57**, 5844-5847.
- 18 TURPIN, J. A. AND WEIGEL, L. O. *Tetrahedron Lett.*, 1992, **33**, 6563-6564.
19. a. CRISPINO, G. A. AND SHARPLESS, K. B. *Synlett*, 1993, 47-48.
b. WANG, Z.-M., ZHANG, X.-L. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1992, **33**, 6407-6410.
- 20 KHANAN, K., SINHA, S. C., SINHA, A.-B., WANG, Z.-M., ZHANG, X.-L. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1992, **33**, 6411-6414.
- 21 BENNANI, Y. L. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1993, **34**, 2083-2086.
- 22 CRISPINO, G. A. AND SHARPLESS, K. B. *Synthesis*, 1993, 777-779.
- 23 WATSON, K. G., FUNG, Y. M., GREDLEY, M., BIRD, G. J., JACKSON, W. R., ÜNTZOS, H. G. AND MATTHEWS, B. R. *J. Chem. Soc., Chem. Commun.*, 1990, 1018-1019.
- 24 RAMA RAO, A. V., GURJAR, M. K. AND JOSHI, S. V. *Tetrahedron Asymmetry*, 1990, **1**, 697-698.
- 25 RAMARAO, A. V., PRAHLADARAO, S. AND BHANU, M. N. *J. Chem. Soc., Chem. Commun.*, 1992, 859-860.
- 26 KOLB, H. C., BENNANI, Y. L. AND SHARPLESS, K. B. *Tetrahedron Asymmetry*, 1993, **4**, 133-141.
- 27 MASAMUNE, S., CHOY, W., PETERSEN, J. S. AND RITA, L. R. *Angew. Chem. Int. Ed. Engl.*, 1985, **24**, 1-30.
- 28 ANNUNZIATA, R., CINQUINI, M., COZZI, F. AND RAIMONDI, L. *Tetrahedron*, 1988, **44**, 6897-6902.
- 29 LOHRAY, B. B., KALANTER, T. H., KIM, B. M., PARK, C. Y., SHIBATA, T., WAI, J. S. M. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1989, **30**, 2041-2044.
- 30 MORIKAWA, K. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1993, **34**, 5575-5578.
- 31 WARD, R. A. AND PROCTER, G. *Tetrahedron Lett.*, 1992, **33**, 3363-3366.

32. PANEK, J. S. AND ZHANG, J. *J Org Chem*, 1993, **58**, 294–296.
33. GURJAR, M. K. AND MAINKAR, A. S. *Tetrahedron Asymmetry*, 1992, **3**, 21–24.
34. LOHRAY, B. B. AND BRUSHAN, V. *Tetrahedron Lett.*, 1993, **34**, 3911–3914.
35. VAN NIEUWENHZE, M. S. AND SHARPLESS, K. B. *J Am Chem. Soc.*, 1993, **115**, 7864–7865.
36. ANNUNZIATA, R., BENAGLIA, M., CINQUINI, M., COZZI, F. AND PONZINI, F. *Bio-Org. Med. Chem. Lett*, 1993, (Personal Communication).
37. GAO, Y. AND SHARPLESS, K. B. *J Am. Chem. Soc.*, 1988, **110**, 7538–7539.
38. LOHRAY, B. B. *Synthesis*, 1992, 1035–1052.
39. LOHRAY, B. B. AND AHUJA, J. R. *J Chem. Soc., Chem Commun*, 1991, 95–97.
- 40.a KONG, S.-K., PARK, Y.-W., LEE, D.-H., AND SIM, H.-S. AND JEON, J.-H. *Tetrahedron Asymmetry*, 1992, **3**, 705–708.
- b. KANG, S.-K., LEE, D.-H., SIM, H.-S., AND LIM, J.-S. *Tetrahedron Asymmetry*, 1992, **3**, 1139–1140.
- c. KONG, S.-K., LEE, D.-H., SIM, H.-S., AND LIM, J.-S. *Tetrahedron Lett.*, 1993, **34**, 91–94.
41. KO, S.Y. AND MALIK, M. *Tetrahedron Lett.*, 1993, **34**, 4675–4678.
- 42.a FLEMING, P. R. AND SHARPLESS, K. B. *J Org. Chem*, 1991, **56**, 2869–2875.
- b. OI, R. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1992, **33**, 2095–2098.
- c. KOLB, H. C. AND SHARPLESS, K. B. *Tetrahedron*, 1992, **48**, 10515–10530.
43. XU, D. AND SHARPLESS, K. B. *Tetrahedron Lett.*, 1993, **34**, 951–952.
44. IIDA, T. AND ITAYA, T. *Tetrahedron*, 1993, **49**, 10511–10530.